8 min read
Monthly FDA Guidance and Regulatory News Review - August 2026
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...
Meet Veristat at ASH Meeting and Exposition December 6-9, 2025
Veristat is excited to attend the ASH Annual Meeting and Exposition, the world’s premier event for cutting-edge research in malignant and non-malignant hematology. This year’s meeting will take place December 6–9, 2025, bringing together global experts to share groundbreaking research and clinical advances in blood disorder research, diagnosis, and treatment.
Meet with Veristat
Gabriela Rosu, M.D. – Vice President, Global Medical Affairs and Pharmacovigilance
Parris Johnson – Senior Business Development Director
Connect with Gabriela and Parris to explore how Veristat’s integrated medical, regulatory, and safety expertise can help you accelerate your hematology programs from early development through approval.
Schedule a Meeting
Reserve time in advance to discuss your upcoming hematology or oncology initiatives.
Expertise That Accelerates Approvals
At Veristat, we understand that every day matters in hematology and oncology drug development. Our multidisciplinary teams bring scientific rigor, regulatory insight, and operational excellence to complex hematology clinical trials, including rare cancers, hematologic malignancies, and gene and cell therapies.
Our expertise spans:
-
Adaptive and biomarker-driven trial designs
Regulatory and statistical strategy for oncology submissions
Global operations for rare and hematologic cancer studies
With more than 480 oncology and hematology studies and 30+ marketing applications supported in the past five years, Veristat helps sponsors turn promising science into approved therapies faster.
We look forward to seeing you at ASH 2025 and exploring how Veristat can help accelerate your hematology and oncology innovations.
Schedule A Meeting
Meet with us at ASH Annual Meeting and Exposition
8 min read
Monthly FDA Guidance and Regulatory News Review - July 2026
Aug 14, 2026 Veristat Blog
This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...